PSTV Stock Overview
A clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Plus Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.21 |
| 52 Week High | US$4.04 |
| 52 Week Low | US$0.97 |
| Beta | 0.55 |
| 1 Month Change | 22.78% |
| 3 Month Change | 3.76% |
| 1 Year Change | -43.77% |
| 3 Year Change | -94.58% |
| 5 Year Change | -98.73% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Plus Therapeutics jumps 18% as JonesTrading adds another Buy rating
Oct 07Plus Therapeutics finalizes $17.6M grant from Texas, to get initial funds by October end
Sep 22Plus Therapeutics GAAP EPS of -$0.24 misses by $0.02
Jul 21Plus Therapeutics CEO Dr. Marc Hedrick - Cancer's Hardest Problems
Dec 21Does Plus Therapeutics (NASDAQ:PSTV) Have A Healthy Balance Sheet?
Aug 25
Plus Therapeutics to proceed with eighth cohort in ReSPECT glioblastoma trial
Jun 16Shareholders May Not Be So Generous With Plus Therapeutics, Inc.'s (NASDAQ:PSTV) CEO Compensation And Here's Why
May 11Plus Therapeutics shares rise 5% on Rhenium NanoLiposome development contract
May 04Is Plus Therapeutics (NASDAQ:PSTV) Using Debt Sensibly?
Feb 23Shareholder Returns
| PSTV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.3% | -0.4% | -0.6% |
| 1Y | -43.8% | 5.5% | 22.2% |
Return vs Industry: PSTV underperformed the US Biotechs industry which returned 5.5% over the past year.
Return vs Market: PSTV underperformed the US Market which returned 22.2% over the past year.
Price Volatility
| PSTV volatility | |
|---|---|
| PSTV Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: PSTV's share price has been volatile over the past 3 months.
Volatility Over Time: PSTV's weekly volatility has decreased from 15% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 20 | Marc Hedrick | plustherapeutics.com |
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection.
Plus Therapeutics, Inc. Fundamentals Summary
| PSTV fundamental statistics | |
|---|---|
| Market cap | US$12.61m |
| Earnings (TTM) | -US$11.77m |
| Revenue (TTM) | US$6.08m |
2.1x
P/S Ratio-1.1x
P/E RatioIs PSTV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PSTV income statement (TTM) | |
|---|---|
| Revenue | US$6.08m |
| Cost of Revenue | US$9.69m |
| Gross Profit | -US$3.61m |
| Other Expenses | US$8.17m |
| Earnings | -US$11.77m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.06 |
| Gross Margin | -59.27% |
| Net Profit Margin | -193.49% |
| Debt/Equity Ratio | -74.2% |
How did PSTV perform over the long term?
See historical performance and comparison